Status asthmaticus

Summary

Status asthmaticus (MONDO:0004766) is a disease and 26 clinical trials. Top therapeutic interventions include montelukast, ipratropium, and water. A subtype of asthma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 26

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	status asthmaticus
Mondo ID	MONDO:0004766
EFO	EFO:0008590
MeSH	D013224
DOID	DOID:9362
NCIT	C122577
SNOMED CT	708090002
UMLS	C0038218
MedGen	11584
Is cancer (heuristic)	no

Disease family

This is a subtype of asthma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › lower respiratory tract disorder › bronchial disorder › asthma › status asthmaticus

Related subtypes (7): cough variant asthma, intrinsic asthma, allergic asthma, childhood onset asthma, occupational asthma, chronic asthma, acute asthma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Ketamine	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Albuterol, Budesonide, Helium, Montelukast, Oxygen, Sodium Chloride.

Clinical trials & evidence

Clinical trials

Clinical trials: 26.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	12
PHASE2	4
PHASE4	3
PHASE2/PHASE3	3
PHASE1	3
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00124995	PHASE4	COMPLETED	Trial of Terbutaline for the Treatment of Status Asthmaticus in Children
NCT02780479	PHASE4	TERMINATED	Steroids in Children Hospitalized With Asthma
NCT02966184	PHASE4	TERMINATED	Comparison of Albuterol for Status Asthmaticus
NCT00491790	PHASE2/PHASE3	UNKNOWN	Montelukast With Status Asthmaticus, Ages 2-5
NCT00494572	PHASE2/PHASE3	UNKNOWN	Montelukast With Status Asthmaticus, Ages 6-18
NCT01524198	PHASE2/PHASE3	COMPLETED	The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room
NCT03338205	PHASE3	WITHDRAWN	The Role of Ketamine as an Adjuvant Therapy for Children With Acute Status Asthmaticus
NCT05819541	PHASE2	RECRUITING	Treating Exacerbations of Asthma With Oral Montelukast in Children
NCT00410150	PHASE2	TERMINATED	Heliox-Powered Albuterol Therapy in the Treatment of Children Admitted With Acute Asthma Exacerbation
NCT00683449	PHASE2	TERMINATED	Study Evaluating the Safety and Effects of MN-221 in Subjects Experiencing an Acute Exacerbation of Asthma
NCT01403428	PHASE2	WITHDRAWN	Non Invasive Positive Pressure Ventilation in Status Asthmaticus
NCT01188473	PHASE1	WITHDRAWN	Early Noninvasive Positive Pressure Ventilation in Children With Status Asthmaticus
NCT02872597	PHASE1	COMPLETED	Phase I, Placebo-Controlled, Blinded Pilot Study of Ipratropium in Children Admitted to the ICU With Status Asthmaticus
NCT04929626	PHASE1	COMPLETED	Different Doses of Nebulized Magnesium Sulphate in Status Asthmaticus
NCT00279786	Not specified	COMPLETED	B2-Adrenergic Receptor Polymorphisms
NCT00623688	Not specified	COMPLETED	Effectiveness and Cost Study Comparing Two Ways to Deliver Albuterol for the Treatment of Asthma in the Hospital
NCT00722020	Not specified	COMPLETED	HFCWO in Hospitalized Asthmatic Children
NCT00750568	Not specified	UNKNOWN	Intravenous Terbutaline in Severe Status Asthmaticus
NCT01770899	Not specified	UNKNOWN	Evaluation Montelukast in the Treatment of Status Asthmaticus
NCT02302261	Not specified	COMPLETED	Pleth Variability and Asthma Severity in Children
NCT02347462	Not specified	WITHDRAWN	Bilevel Positive Airway Pressure (BiPAP) for the Treatment of Moderate to Severe Acute Asthma Exacerbations
NCT02539420	Not specified	WITHDRAWN	A Prospective Trial of BiPAP Administration vs. Non-positive Pressure Therapy for Pediatric Status Asthmaticus
NCT03157102	Not specified	COMPLETED	High Flow Nasal Cannula in Children With Status Asthmaticus
NCT03219736	Not specified	WITHDRAWN	NiPPV in the Treatment of Acute Asthma Exacerbations
NCT03742167	Not specified	COMPLETED	Pilot Simulation RCT of Telemedical Support for Paramedics
NCT04656587	Not specified	WITHDRAWN	BPAP in Pediatric Asthma Pilot Study

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
MONTELUKAST	4	3
IPRATROPIUM	4	2
WATER	4	2
ALBUTEROL	4	1
PREDNISONE	4	1
TERBUTALINE	4	1
MAGNESIUM	3	1
BEDORADRINE SULFATE	2	1
CHEMBL5205127	0	2
CHEMBL15720	0	1
CHEMBL1908368	0	1
CHEMBL4576512	0	1